Nastaran Barati - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
Atefeh Razazan - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
Jessica Nicastrob - bSchool of Pharmacy, University of Waterloo, ۲۰۰ University Ave W., Waterloo, N۲L۳G۱, Canada. Waterloo Institute of Nanotechnology, University of Waterloo, ۲۰۰ University Ave W., Waterloo, N۲L۳G۱, Canada
Roderick Slavcev - School of Pharmacy, University of Waterloo, ۲۰۰ University Ave W., Waterloo, N۲L۳G۱, Canada Waterloo Institute of Nanotechnology, University of Waterloo, ۲۰۰ University Ave W., Waterloo, N۲L۳G۱, Canada. Mediphage Bioceuticals, Inc., ۶۶۱ University Avenue,
Atefeh Arab - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
Fatemeh Mosaffa - Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran. Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Phage display technique has been increasingly researched for vaccine design and delivery strategies in recent years. In this study, the AE37 (Ii-Key/HER-2/neu 776–790) peptide derived from HER2 (human epidermal growth factor receptor protein) was used as a fused peptide to the lambda phage (λF7) coat protein gpD, and the phage nanoparticles were used to induce antitumor immunogenicity in a TUBO model of breast cancer in mice. Mice were immunized with the AE37 peptide displaying phage, λF7 (gpD::AE37) every 2-week intervals over 6-weeks, then the generated immune responses were evaluated. An induction of CTL immune response by the λF7 (gpD::AE37) construct compared to the control λF7 and buffer groups was observed in vitro. Moreover, in the in vivo studies, the vaccine candidate showed promising prophylactic and therapeutic effects against the HER2 overexpressing cancer in BALB/c mice.